Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787995 · ClinicalTrials.gov registry record
A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Terminated
- Registry status
- 353
- Enrollment target
NCT00787995: Clinical Trial study, sponsored by BioMarin Pharmaceutical.
NCT00787995 is a clinical trial that was terminated before completion, run by BioMarin Pharmaceutical. The registered enrollment target is 353 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00787995 was terminated before completion, sponsored by BioMarin Pharmaceutical.
- TERMINATED
- Registry status
- 353 participants
- Enrollment target
Study Summary
This multicenter, multinational, longitudinal study will quantify endurance and respiratory function in subjects diagnosed with MPS IVA and will better characterize the spectrum of symptoms and biochemical abnormalities in MPS IVA disease over time.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2008-10 |
| Est. Completion | 2014-07 |
Why NCT00787995 stopped before completion
NCT00787995 is an observational study that tracks outcomes without assigning an intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00787995 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00787995 about?
NCT00787995 is a clinical study titled "A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)". This multicenter, multinational, longitudinal study will quantify endurance and respiratory function in subjects diagnosed with MPS IVA and will better characterize the spectrum of symptoms and biochemical abnormalities in MPS IVA disease over time.
What is the current status of trial NCT00787995?
This trial is currently terminated. The enrollment target is 353 participants. The study started on 2008-10. Estimated completion is 2014-07.
Who is sponsoring clinical trial NCT00787995?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia